30 March 2022 : Clinical Research
Follow-Up of 108 Patients with Chronic Hepatitis B Virus Infection Treated with Polyethylene Glycol-Conjugated Derivatives of Interferon-Alpha and Monitoring of Off-Treatment Virological Relapse
Liyang Zhou1ABCDEF, Qin He1CEF, Xitao Liu2DEF, Xiaoan Yang3BC, Xueting Ou3EF, Bing Situ2DF, Yueping Li4DE, Xingfei Pan1DEFG*, Qihuan Xu3AEDOI: 10.12659/MSM.934785
Med Sci Monit 2022; 28:e934785
Table 3 Univariate and multivariate Cox analysis of factors associated with sustained virological suppression after pegylated interferon-alpha regimen was completed.
Factors | Univariate | Multivariate | ||
---|---|---|---|---|
RR (95% CI) | P | RR (95% CI) | P | |
HBsAg at 24 weeks | 1.000 (1.000~1.000) | 0.022 | 1.000 (1.000~1.000) | 0.816 |
HBsAg at 36 weeks | 1.000 (1.000~1.000) | 0.000 | 1.000 (1.000~1.000) | 0.717 |
HBsAg at 48 weeks | 1.000 (1.000~1.000) | 0.000 | 1.000 (1.000~1.000) | 0.331 |
HBV DNA at 36 weeks | 1.000 (1.000~1.000) | 0.028 | 1.000 (1.000~1.000) | 0.096 |
HBV DNA at 48 weeks | 1.000 (1.000~1.000) | 0.025 | 1.000 (1.000~1.000) | 0.345 |
AST at 24 weeks | 0.988 (0.978~0.999) | 0.029 | 0.988 (0.975~1.002) | 0.088 |
Time of treatment | 0.961 (0.932~0.992) | 0.013 | 0.991 (0.958~1.026) | 0.614 |
ALT at 24 weeks of follow-up | 5.027 (2.610~9.682) | 0.000 | 3.430 (1.302~9.034) | 0.013 |
Peg-IFNα – pegylated interferon alfa; HBsAg – hepatitis B surface antigen; HBV – hepatitis B virus; ALT – alanine aminotransferase; AST – aspartate aminotransferase. |